This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.
Novartis drug works in secondary progressive MS. Orally-active siponimod reduces risk of disability progression. ... The new drug candidate - called siponimod (BAF312) - reduced the risk of disability progression compared with placebo in the
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...